Lilly Lets Hims & Hers Prescribe Zepbound and Foundayo at Self-Pay Prices
- Lilly will offer Zepbound and its oral Foundayo through the Hims & Hers telehealth platform at the same self-pay prices available elsewhere, starting at $299 and $149 a month respectively.
- Hims previously sold cheaper compounded GLP-1s and changed course in March after a legal challenge from Novo, which struck a similar deal with it.
💡 Points Based on public reports
Both big GLP-1 makers now use Hims as a cash-pay channel, which turns a former adversary into distribution and removes the compounded-versus-branded argument from the telehealth funnel. For Lilly the signal is price discipline: self-pay tiers are set low enough that volume, not margin per script, is the bet. Watch whether Hims keeps compounded options for 'clinical necessity'.
Lilly, Hims reach GLP-1 deal; Alnylam sales chief to step down ↗